Ads
related to: Patents and Vaccines
Search results
Emcure, HDT settle legal fight over COVID vaccine technology
Reuters· 6 days ago, opens new tab and U.S. vaccine developer HDT Bio have settled allegations that Emcure stole HDT...
CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update
Digital Journal· 6 days agoOrganizational redesign on track, trimming residual pandemic infrastructure and reducing 150 positions by year endU.S. FDA Fast Track designation granted for pre-pandemic avian influenza (H5N1 ...
Scripps Scientists Pioneer Vaccine To Combat Deadly “Zombie Drug” Xylazine
SciTechDaily· 5 days agoChemical biologists at Scripps Research have developed a preliminary “proof-of-concept” vaccine,...
Emcure, HDT settle legal fight over COVID vaccine technology
WHTC 1450 Holland· 6 days agoBy Blake Brittain (Reuters) - Indian generic drugmaker Emcure Pharmaceuticals and U.S. vaccine developer HDT Bio have settled allegations that Emcure stole HDT trade secrets ...
JD Supra: World IP Day - Celebrating Innovation and Creativity to Build Our Common Future
JD Supra· 4 days agoIP is again being celebrated this year on April 26, with the World Intellectual Property Organization paying homage to the intersection of IP and the Sustainable Development Goals...
Jim Cramer: Celestica Makes A 'Comeback,' Sell This Movie Theater Stock, - Moderna (NASDAQ:MRNA)
Benzinga· 2 days agoJim Cramer called Celestica Inc. "terrific" after the Toronto-based company reported...
Scientists develop edible antiviral treatment for crucial pollinator: 'The engineered algae boost...
The Cool Down via Yahoo News· 7 days agoThat's great news for beekeepers and farmers. And since the algae mixes right into existing bee...
NIH Seeks Comments on Patient Access Plan Requirements in Patent License Agreements | JD Supra
JD Supra· 24 hours agoThe Situation: The National Institutes of Health ("NIH") proposed a new policy requiring entities that receive licenses from the NIH to certain taxpayer-funded inventions to submit Access Plans ...
Should You Buy This Stock After a Regulatory Setback? | The Motley Fool
The Motley Fool· 4 days agoThe past two-and-a-half years have been rough for Moderna (MRNA 1.58%). The company is developing...
Merck to buy eye-focused drug developer EyeBio for as much as $3 bln
Reuters· 17 hours agoThe deal is the latest in a string of recent acquisitions by Merck to reduce its reliance on...